Background Rheumatoid arthritis (RA) is a chronic, inflammatory disease of the joints with multisystemic involvement. Endothelial dysfunction caused by inflammatory process increases the risk of cardiovascular disease (CVD). As a consequence the morbidity and mortality in these patients is increasing. Flow mediated dilatation (FMD) is a radiological method that demonstrate endothelial dysfunction. At earlier studies ADMA correlated with FMD, in showing endothelial dysfunction, can be used as a simple and a cheaper method.
Objectives At earlier studies asymmetric dimethylarginine (ADMA) correlated with FMD, in showing endothelial dysfunction, can be used as a simple and a cheaper method. In this study we assessed the availability of ADMA as a marker shoving endothelial dysfunction in RA patients.
Methods We have studied 40 patients below age of 65, which were diagnosed as RA by 1987 ARA classification criteria and have taken 29, age matched and healthy, non-smoking controls. Exclusion criterias were the diagnosis of coronary and peripheral artery disease, hypertension, diabetes mellitus, smoking and renal failure. FMD and ADMA levels were measured in all patients and controls. We also assessed the affect of disease activity and severity on vascular functions in this study. Therefore DAS28, CRP, ESR and anti-CCP and RF levels were measured, and the relationship between these markers and endothelial dysfunction were evaluated.
Results In our study, ADMA levels were significantly higher in RA patients and were inversely correlated with FMD. Disease duration and age of the patients affected ADMA levels. Relationship between impairment in vascular function and disease activity parameters was not detected. Significant association with anti-CCP positivity was not seen either.
Conclusions The result obtained in our study, supports the hypothesis that ADMA can be used in the assessment of endothelial dysfunction in patients with RA.
Disclosure of Interest None declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.